Michael Schmertzler, Director at PTC THERAPEUTICS, INC. (PTCT), bought 66,225 shares at $30.20 ($2.0M) on 2019-01-25, disclosed to the SEC on 2019-01-29.
Open-market purchase of $2.0M PTCT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| PTCT | SELL | 2026-09-18 | $1.3M | — | Filing → |
| PTCT | SELL | 2026-09-11 | $1.4M | — | Filing → |
| PTCT | SELL | 2026-08-28 | $1.8M | — | Filing → |